12 Dec 2022 --- Bioscience players Novozymes and Chr. Hansen are merging in a deal that will result in the dissolution of the latter by the fourth quarter of 2023. The new company is expected to post annual revenues upwards of €3.5 billion (US$3.7 billion).
